InflaRx (IFRX) Interest Expenses (2016 - 2026)
InflaRx (IFRX) posted Interest Expenses of -$17713.4 for Q1 2026, down 162.13% sequentially from $28509.8 in Q4 2025, and down 301.81% YoY from $8777.5 in Q1 2025.
InflaRx (IFRX) Interest Expenses (2016 - 2026) Analysis & Trends
InflaRx has reported Interest Expenses for 11 years, with the latest figure at -$17713.4 in Q1 2026.
- Quarterly Interest Expenses fell 301.81% year-over-year to -$17713.4 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2192.4 (down 105.58% YoY) and the FY2025 annual result came in at $44332.7, up 94.46% from the prior year.
- Interest Expenses declined to -$17713.4 in Q1 2026 per IFRX's latest filing, from $28509.8 in the prior quarter.
- Over five years, Interest Expenses peaked at $39802.0 in Q4 2024 and troughed at -$5.9 billion in Q1 2023.
- A 5-year average of -$349.0 million and a median of -$5330.8 in 2023 frame the typical range for Interest Expenses.
- The widest YoY moves for Interest Expenses: up 711.76% in 2023, down 21454686.53% in 2023.
- Over 5 years, Interest Expenses stood at -$5682.8 in 2022, then jumped by 711.76% to $34764.7 in 2023, then increased by 14.49% to $39802.0 in 2024, then decreased by 28.37% to $28509.8 in 2025, then plunged by 162.13% to -$17713.4 in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered -$17713.4, $28509.8, and -$16786.5 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | -17,020.46 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17,713.38 |
| Mar 31, 2026 | -17,713.38 |
| Dec 31, 2025 | 28,509.75 |
| Dec 31, 2025 | 28,509.75 |
| Sep 30, 2025 | -16,786.46 |
| Sep 30, 2025 | -16,786.46 |
| Jun 30, 2025 | 3,797.72 |
| Jun 30, 2025 | 3,797.72 |
| Mar 31, 2025 | -4,408.45 |
| Mar 31, 2025 | -4,408.45 |
| Dec 31, 2024 | 39,801.97 |
| Dec 31, 2024 | 39,801.97 |
| Sep 30, 2024 | -5,526.24 |
| Sep 30, 2024 | -5,526.24 |
| Jun 30, 2024 | 9,403.38 |
| Jun 30, 2024 | 9,403.38 |
| Mar 31, 2024 | -5,032.03 |
| Mar 31, 2024 | -5,032.03 |
| Dec 31, 2023 | 34,764.69 |
| Dec 31, 2023 | 34,764.69 |